Skip to main content

Table 1 Baseline characteristics of study patients (n = 90)

From: Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

 

Nintedanib (n = 39)

Pirfenidone (n = 51)

p-value

Age, years

70 (7)

72 (7)

0.22

Male sex – no. (%)

35 (90)

47 (92)

0.72

FVC % predicted

86 (16)

76 (16)

0.01

FVC (L)

3.4 (0.9)

2.9 (0.6)

0.01

DLCO % predicted

48 (14)

49 (14)

0.69

K-BILD total score

56.5 (9)

56.7 (10)

0.89

EQ 5D-Index value

0.78 (0.15)

0.77 (0.19)

0.78

EQ5D-VAS scale

65 (24)

63 (23)

0.66

VAS – cough*

4.8 (2.6)

4.6 (2.5)

0.66

VAS – dyspnea*

5.1 (2.3)

5.6 (2.4)

0.43

VAS – general complaints**

5.6 (2.4)

5.5 (2.4)

0.75

HADS – depression score

3.0 (3.1)

3.9 (3.5)

0.21

HADS – anxiety score

4.7 (2.3)

4.6 (2.3)

0.94

  1. Data are presented as mean (SD). FVC forced vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, K-BILD King’s Brief Interstitial Lung Disease questionnaire, VAS visual analogue scale, HADS Hospital Anxiety and Depression Scale. * a higher score represent worse symptoms, ** a higher score represents fewer symptoms
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us